Combined Use of Naldebain® ER Injection and Precedex® After VATS

• Status: Not yet recruiting
• Trial end date: 2026-03-31
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical trial is to investigate the effects of combined use of Naldebain® ER Injection and Precedex® in patients received video-assisted thoracoscopic surgery. The main questions it aims to answer are:

• the pain intensity after surgery

• the level of dizziness after surgery Participants will receice ultrasound-guided thoracic paravertebral nerve block, intramuscular Naldebain® ER injection and intravenous Precedex® infusion.

If there is a comparison group: Researchers will compare experimental group with placebo group to see if pain and dizziness after surgery can reduced.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

1. Subject's age: 18~65 years old

2. ASA classification: I~III Exclusion Criteria:

3. Patients who need postoperative pain relief due to thoracoscopic surgery

Exclusion Criteria:

1. The patient suffers from a communication disorder

2. The patient has coagulopathy

3. Sick with obvious heart, lung, liver or kidney disease

4. The patient's body mass index is less than 18.5 or greater than 35

5. Pregnant patients

6. Patients who took opioids for more than three weeks before surgery

7. Patients with contraindications to local anesthesia

8. Patients with a history of chronic pain

9. Patients with a history of drug allergy to Naldebain® ER Injection, COX2-inhibitor NSAIDs (such as parecoxib), or Precedex®